London-based healthcare comms agency Road has been appointed by Helperby Therapeutics to provide communications around its work on antimicrobial resistance.
Road will be launching offline, digital and social media programmes to engage the medical and investment communities in conversations around antibiotics and resistance.
Helperyby is working on antiobiotic technology that it hopes will battle microbial resistance by combining new resistance breakers with existing antibiotics to create a “new generation of therapies”.
Frances Crewsdon, chief operating officer at Helperby, said: “There has been no new class of antibiotic produced over thirty years.
“This new lease of life for antibiotics has the potential to help sustain our defence against life threatening superbugs for years to come.”
The threat of antimicrobial resistance continues to attract a high-level response, most recently with the EU bringing together stakeholders across Europe last month to define common policies to fight AMR and control hospital-acquired infections.